Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchThermotherapyThermotherapy (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Thermotherapy for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, October 2024, Version 1V1
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Huang (RCT) 40% 0.60 [0.16-2.25] hosp. 3/25 5/25 diathermy Huang (RCT) 67% 0.33 [0.16-0.70] no recov. 6/25 18/25 diathermy Huang (RCT) 15% 0.85 [0.72-0.99] recov. time 25 (n) 25 (n) diathermy Huang (RCT) 67% 0.33 [0.12-0.90] no recov. 25 (n) 25 (n) diathermy Huang (RCT) 67% 0.33 [0.17-0.67] no recov. 25 (n) 25 (n) diathermy Huang (RCT) 80% 0.20 [0.01-3.97] viral+ 0/25 2/25 diathermy Huang (RCT) 50% 0.50 [0.14-1.78] viral+ 3/25 6/25 diathermy Huang (RCT) -57% 1.57 [0.73-3.39] viral+ 11/25 7/25 diathermy Huang (RCT) -28% 1.28 [0.98-1.67] viral+ 23/25 18/25 diathermy Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Dominguez-Nicolas 93% 0.07 [0.01-0.48] no improv. 0/17 3/5 LF-ThMS Dominguez-Nicolas 93% 0.07 [0.01-0.48] no improv. 0/17 3/5 LF-ThMS Dominguez-Nicolas 96% 0.04 [0.00-0.68] no improv. 0/17 5/5 LF-ThMS Dominguez-Nicolas 82% 0.18 [0.07-0.47] no improv. 3/17 5/5 LF-ThMS Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Dominguez-Nicolas 35% 0.65 [0.30-1.39] no improv. 11/17 5/5 LF-ThMS Dominguez-Nicolas 35% 0.65 [0.30-1.39] no improv. 11/17 5/5 LF-ThMS Dominguez-Nicolas 18% 0.82 [0.59-1.15] no improv. 14/17 5/5 LF-ThMS Dominguez-Nicolas 18% 0.82 [0.59-1.15] no improv. 14/17 5/5 LF-ThMS Dominguez-Nicolas 12% 0.88 [0.65-1.20] no improv. 15/17 5/5 LF-ThMS Dominguez-Nicolas 6% 0.94 [0.71-1.24] no improv. 16/17 5/5 LF-ThMS Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Tian (DB RCT) 76% 0.24 [0.05-1.15] ICU 2/27 4/13 diathermy Tian (DB RCT) 67% 0.33 [0.15-0.72] no recov. 27 (n) 13 (n) diathermy Tian (DB RCT) 73% 0.27 [0.11-0.67] no recov. 27 (n) 13 (n) diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients Excluded Bonfanti (RCT) 26% 0.74 [0.16-3.48] death 2/9 3/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.14-2.25] death 3/54 5/51 heating pad TherMoCoV Mancilla-G.. (RCT) 21% 0.79 [0.26-2.42] ventilation 5/54 6/51 heating pad TherMoCoV Mancilla-G.. (RCT) 17% 0.83 [0.45-1.52] progression 14/54 16/51 heating pad Thermotherapy COVID-19 outcomes c19early.org October 2024 Favors thermotherapy Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit